参莲胶囊联合贝伐珠单抗和FOLFOX方案治疗晚期胃癌的临床研究  

Clinical study on Shenlian Capsules combined with bevacizumab and FOLFOX chemotherapy scheme in treatment of advanced gastric cancer

作　　者：潘静 许培培 连慧娟 袁惠芳 PAN Jing;XU Pei-pei;LIAN Hui-juan;YUAN Hui-fang(Department of Oncology,Zhengzhou Yihe Hospital,Zhengzhou 450000,China;Department of Pediatric General Surgery,the Third Affiliated Hospital of Zhengzhou University,Zhengzhou 450000,China)

机构地区：[1]郑州颐和医院肿瘤内科,河南郑州450000 [2]郑州大学第三附属医院小儿普外科,河南郑州450000

出　　处：《现代药物与临床》2021年第12期2596-2600,共5页Drugs & Clinic

基　　金：河南省医学科技攻关计划联合共建项目(LHGJ20190394)。

摘　　要：目的观察参莲胶囊联合贝伐珠单抗注射液和FOLFOX方案(奥沙利铂、亚叶酸钙联合5-氟尿嘧啶)治疗晚期胃癌的临床疗效。方法选取2019年3月—2020年11月郑州颐和医院收治的60例晚期胃癌患者,入选患者采用双色球法分为对照组和治疗组,每组各30例。对照组给予FOLFOX化疗方案,第1天静脉滴注注射用奥沙利铂,85 mg/m^(2)溶于0.9%氯化钠溶液100 mL中。第1、2天静脉滴注注射用亚叶酸钙,200 mg/m^(2)溶于0.9%氯化钠溶液100 mL中,滴注完成后静脉推注氟尿嘧啶注射液,400 mg/m^(2)。第1天静脉滴注贝伐珠单抗注射液,7.5 mg/kg溶于0.9%氯化钠溶液100 mL中。治疗组在对照组的基础上口服参莲胶囊,6粒/次,3次/d。两组均以3周为1个周期,持续治疗3个周期。观察两组疗效,比较两组生存质量、血清肿瘤标志物水平。结果治疗后,治疗组患者的客观缓解率(ORR)、疾病控制率(CBR)均高于对照组(P<0.05)。治疗后,治疗组患者生存质量提高率明显高于对照组,生存质量降低率低于对照组(P<0.05)。治疗后,两组血清糖链抗原199(CA199)、癌胚抗原(CEA)、胃癌抗原(CA724)水平降低(P<0.05),且治疗组的血清CA199、CEA、CA724水平明显低于对照组(P<0.05)。结论参莲胶囊联合贝伐珠单抗注射液和FOLFOX方案治疗晚期胃癌的疗效显著,可改善患者生存质量,有效降低血清肿瘤标志物水平,安全性较好。Objective To observe the clinical efficacy of Shenlian Capsules combined with Bevacizumab Injection and FOLFOX chemotherapy scheme(oxaliplatin, calcium folinate combined with fluorouracil) in treatment of advanced gastric cancer. Methods Patients(60 cases) with advanced gastric cancer in Zhengzhou Yihe Hospital from March 2019 to November 2020 were randomly divided into control and treatment groups, and each group had 30 cases. Patients in the control group were given FOLFOX chemotherapy scheme: the first day, patients in the control group iv administered with Oxaliplatin for injection, 85 mg/m^(2)added into 0.9% sodium chloride solution 100 mL;the first and second day, patients in the control group iv administered with Calcium Folinate for injection, 200 mg/m^(2)added into 0.9% sodium chloride solution 100 mL, after the infusion, Fluorouracil for injection was injected intravenously, 400 mg/m^(2). On the first day, patients in the control group iv administered with Bevacizumab Injection, 7.5 mg/kg added into 0.9% sodium chloride solution 100 mL. Patients in the treatment group were po administered with Shenlian Capsules on the basis of the control group, 6 grains/time, three times daily. Three weeks was a treatment cycle, and patients in two groups were treated for 4 treatment cycles. After treatment, the clinical efficacies were evaluated, and the quality of life and the serum tumor markers in two groups were compared. Results After treatment, the objective remission rate(ORR) and disease control rate(CBR) in the treatment group were higher than those in the control group(P < 0.05). After treatment, the improvement rate of quality of life in the treatment group was significantly higher than that in the control group, and the reduction rate of quality of life in the treatment group was lower than that in the control group(P < 0.05). After treatment, the serum levels of CA199, CEA, and CA724 in two groups were significantly decreased(P < 0.05), and the serum levels of CA199, CEA, and CA724 in the treatment group

关 键 词：参莲胶囊 贝伐珠单抗注射液 FOLFOX方案 注射用奥沙利铂 注射用亚叶酸钙 氟尿嘧啶注射液 晚期胃癌 生存质量 血清肿瘤标志物 

分 类 号：R979.1[医药卫生—药品]